Zetomipzomib (KZR-616) is the first immunoproteasome inhibitor that selectively targets the immunoproteasome subunits LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7). Zetomipzomib has potential for use in a variety of autoimmune diseases.
Molecular Weight:
586.68
Purity:
>99%
CAS Number:
[1629677-75-3]
Formula:
C30H42N4O8
Target:
Proteasome
* VAT and and shipping costs not included. Errors and price changes excepted